Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function
Treatment of choice of metastatic hormone-dependent breast cancer regardless of age is hormone therapy (HT) even with visceral metastases. Now we have a new class of drugs called inhibitors of cyclin-dependent kinases 4/6, which significantly increase effectiveness of HT and prevent development of r...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2018-11-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2743 |
| _version_ | 1797841476263084032 |
|---|---|
| author | S. F. Menshikova M. A. Frolova E. V. Glazkova M. B. Stenina |
| author_facet | S. F. Menshikova M. A. Frolova E. V. Glazkova M. B. Stenina |
| author_sort | S. F. Menshikova |
| collection | DOAJ |
| description | Treatment of choice of metastatic hormone-dependent breast cancer regardless of age is hormone therapy (HT) even with visceral metastases. Now we have a new class of drugs called inhibitors of cyclin-dependent kinases 4/6, which significantly increase effectiveness of HT and prevent development of resistance to HT. In MONALEESA-7 inhibitor of cyclin-dependent kinases 4/6 ribociclib was studied in combination with ovarian suppression and hormone therapy in young patients with preserved ovarian function, and found no differences in the efficacy and safety of these drugs compared with menopausal patients. Our clinical experience strongly demonstrates the safety and efficacy of ribociclib in combination with HT and ovarian suppression in premenopausal patient with visceral metastases. |
| first_indexed | 2024-04-09T16:31:30Z |
| format | Article |
| id | doaj.art-13b79c9efaba4013bdb873623360288f |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:31:30Z |
| publishDate | 2018-11-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-13b79c9efaba4013bdb873623360288f2023-04-23T06:57:04ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-11-01019283010.21518/2079-701X-2018-19-28-302685Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian functionS. F. Menshikova0M. A. Frolova1E. V. Glazkova2M. B. Stenina3FSAEI HE I.M. Sechenov First Moscow State Medical University оf the Ministry of Health of the Russian Federation (Sechenov University)FSBI «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian FederationFSBI «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian FederationFSBI «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian FederationTreatment of choice of metastatic hormone-dependent breast cancer regardless of age is hormone therapy (HT) even with visceral metastases. Now we have a new class of drugs called inhibitors of cyclin-dependent kinases 4/6, which significantly increase effectiveness of HT and prevent development of resistance to HT. In MONALEESA-7 inhibitor of cyclin-dependent kinases 4/6 ribociclib was studied in combination with ovarian suppression and hormone therapy in young patients with preserved ovarian function, and found no differences in the efficacy and safety of these drugs compared with menopausal patients. Our clinical experience strongly demonstrates the safety and efficacy of ribociclib in combination with HT and ovarian suppression in premenopausal patient with visceral metastases.https://www.med-sovet.pro/jour/article/view/2743metastatic hormone-dependent breast cancerhormone therapycyclin-dependent kinase inhibitorsribociclib |
| spellingShingle | S. F. Menshikova M. A. Frolova E. V. Glazkova M. B. Stenina Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function Медицинский совет metastatic hormone-dependent breast cancer hormone therapy cyclin-dependent kinase inhibitors ribociclib |
| title | Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function |
| title_full | Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function |
| title_fullStr | Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function |
| title_full_unstemmed | Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function |
| title_short | Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function |
| title_sort | ribociclib in the first line therapy for metastatic hormone dependent her2 negative breast cancer in patients with intact ovarian function |
| topic | metastatic hormone-dependent breast cancer hormone therapy cyclin-dependent kinase inhibitors ribociclib |
| url | https://www.med-sovet.pro/jour/article/view/2743 |
| work_keys_str_mv | AT sfmenshikova ribociclibinthefirstlinetherapyformetastatichormonedependenther2negativebreastcancerinpatientswithintactovarianfunction AT mafrolova ribociclibinthefirstlinetherapyformetastatichormonedependenther2negativebreastcancerinpatientswithintactovarianfunction AT evglazkova ribociclibinthefirstlinetherapyformetastatichormonedependenther2negativebreastcancerinpatientswithintactovarianfunction AT mbstenina ribociclibinthefirstlinetherapyformetastatichormonedependenther2negativebreastcancerinpatientswithintactovarianfunction |